E3 PreliminaryPreliminaryPEM ?Peer-reviewedMachine draft
Successful Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with Chronic Febricula Using the Traditional Japanese Medicine Shosaikoto.
Numata, Takehiro, Miura, Kazuki, Akaishi, Tetsuya et al. · Internal medicine (Tokyo, Japan) · 2020 · DOI
Quick Summary
A 14-year-old girl with ME/CFS who had experienced severe tiredness, low-grade fevers, and school absence for 20 months was treated with shosaikoto, a traditional Japanese herbal medicine. Within several weeks, her symptoms improved dramatically and she was able to return to school. This case suggests that shosaikoto may help some ME/CFS patients, particularly those with persistent low fevers.
Why It Matters
Treatment options for ME/CFS remain limited, and this case raises the possibility that traditional herbal medicines warrant investigation in rigorously designed trials. The observation that a patient with a specific ME/CFS phenotype (chronic febricula) responded to this intervention could help guide future research into personalized treatment approaches based on symptom subtypes.
Observed Findings
- 14-year-old female with 20-month history of chronic fatigue, febricula, and social withdrawal unresponsive to symptomatic treatment
- Dramatic alleviation of all reported symptoms within several weeks of shosaikoto-based treatment initiation
- Resolution of school non-attendance following treatment response
- No abnormalities detected on routine pediatric hospital evaluation prior to treatment
Inferred Conclusions
- Shosaikoto-based treatment may be a therapeutic option for ME/CFS patients presenting with chronic febricula
- Traditional Japanese medicine frameworks may offer clinically relevant approaches for ME/CFS management in select patient populations
Remaining Questions
- Would shosaikoto be effective in other ME/CFS patients without chronic febricula, or is this response specific to the febricula phenotype?
- What is the mechanism of action of shosaikoto in this clinical context, and which components (if any) are therapeutically active?
- How long do treatment benefits persist, and what is the relapse rate after discontinuation?
- Could these improvements be replicated in a controlled trial with objective outcome measures and blinded assessment?
What This Study Does Not Prove
This single case cannot prove that shosaikoto is an effective ME/CFS treatment. It does not establish whether the improvement was due to the medication, placebo effect, natural disease fluctuation, or other concurrent factors. Large randomized controlled trials would be needed to determine efficacy and safety.
Tags
Symptom:FatigueTemperature Dysregulation
Phenotype:Pediatric
Method Flag:PEM Not DefinedWeak Case DefinitionNo ControlsSmall SampleExploratory Only